HHS/ASPE. U. S. Department of Health and Human Services.Background

Research Subcommittee Recommendations

January 14, 2014

PDF Version: http://aspe.hhs.gov/daltcp/napa/020314/Mtg11-Recom3.pdf (5 PDF pages)

  1. In order to support the goal to prevent and effectively treat Alzheimer's Disease by 2025, and to continue to develop a clear roadmap of research and treatment discovery priorities and timelines, we recommend that the interim research milestones first established in 2013 be evaluated and updated each year, to assure continuing and successful progress toward achievement of this goal.
  2. The urgent need for increased annual federal research funding sufficient to fund the strategic research plan reflected in the NIH milestones and to achieve the breakthroughs required to meet the 2025 goal remains a top priority. Initial estimates of that level are $2 billion per year but may be more. That investment would be applied to Alzheimer's research initiatives spanning basic, translational and clinical research.
  3. Based on the recommendations of the 2013 ADRD Research Workshop, interim milestones for achieving specific research goals for the study of Alzheimer's Disease Related Disorders (i.e., Frontotemporal Degeneration (FTD), Lewy Body Dementia (LBD) and vascular contributions to ADRD) should be explicitly added to the National Plan.
  4. We recommend that HHS, in partnership with experts from the research community and industry, take steps to accelerate public access to new therapeutic interventions by compressing the current average time in the process of identification of therapeutic targets, validation of those targets, development of behavioral and pharmacologic interventions, testing of efficacy and safety, and regulatory review, by:
  5. We recommend that the Administration build on the commitments issued at the G8 Dementia Summit in London on December 11, 2013 and take a leadership role in establishing a Global Alzheimer's Action Plan to respond to the global scope of the Alzheimer's challenge. We recommend that this response will include, among other strategies, the following:
    1. A coordinated international research action plan,
    2. A coordinated clinical trial infrastructure for Alzheimer's, including linked patient registries, longitudinal studies and trial-ready patient cohorts,
    3. A global fund to increase collectively and significantly the funding for Alzheimer's research, and
    4. A policy framework designed to provide incentives for additional investment in Alzheimer's research, including improved harmonization of national and regional regulatory regimes regarding Alzheimer's diagnostic and therapeutic products.
  6. We recommend that the Administration designate a specific Office and officials within the White House with responsibility and accountability for effective implementation of, and timely, transparent reporting on, all aspects of the implementation of this National Alzheimer's Plan and of the commitments made by HHS at the G8 Dementia Summit, including any global action plan as it is developed.


Where to?

Top of Page

Home Pages:
Office of Disability, Aging and Long-Term Care Policy (DALTCP)
Assistant Secretary for Planning and Evaluation (ASPE)
U.S. Department of Health and Human Services (HHS)

Please alert us at napa@hhs.gov if you discover broken links

Last updated: 02/03/2014